Vismodegib and risk of cholestatic injury: should we screen candidate patients?

Vismodegib and risk of cholestatic injury: should we screen candidate patients? Clin Exp Med (2017) 17:415–416 DOI 10.1007/s10238-016-0433-2 LETTER TO THE EDITOR Vismodegib and risk of cholestatic injury: should we screen candidate patients? 1 2 1 2 • • • • Michelangelo Vestita Lucia Lospalluti Giuseppe Giudice Domenico Bonamonte 3 2 Ignazio Rossiello Angela Filoni Received: 15 July 2016 / Accepted: 24 July 2016 / Published online: 2 August 2016 Springer International Publishing Switzerland 2016 Dear Sir, tomography, magnetic resonance imaging and endoscopic retrograde cholangiopancreatography. Periportal edema, We have read with interest the paper of Ash et al. [1] along with increased liver volume and mild dilatation of concerning vismodegib-related cholestatic liver injury. We the intrahepatic bile ducts, was noticed (Fig. 1). Minute would like to report our experience with a 71-year-old lithiasic formations were present in the gallbladder, patient who underwent vismodegib therapy for 11 spread choledochus and cystic duct (Fig. 2; Suppl Fig. 1, 2). A cutaneous basal cell carcinoma, of which 4 were recurring single, larger, previously documented, 15 mm lithiasic lesions, and developed intense jaundice by severe element was also evident in the gallbladder. Ash et al. [1] cholestasis and acute liver injury after 3 months of vis- reason on the potential ability of vismodegib to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Experimental Medicine Springer Journals

Vismodegib and risk of cholestatic injury: should we screen candidate patients?

Loading next page...
 
/lp/springer_journal/vismodegib-and-risk-of-cholestatic-injury-should-we-screen-candidate-k5S3gALxVe
Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer International Publishing Switzerland
Subject
Medicine & Public Health; Internal Medicine; Hematology; Oncology
ISSN
1591-8890
eISSN
1591-9528
D.O.I.
10.1007/s10238-016-0433-2
Publisher site
See Article on Publisher Site

Abstract

Clin Exp Med (2017) 17:415–416 DOI 10.1007/s10238-016-0433-2 LETTER TO THE EDITOR Vismodegib and risk of cholestatic injury: should we screen candidate patients? 1 2 1 2 • • • • Michelangelo Vestita Lucia Lospalluti Giuseppe Giudice Domenico Bonamonte 3 2 Ignazio Rossiello Angela Filoni Received: 15 July 2016 / Accepted: 24 July 2016 / Published online: 2 August 2016 Springer International Publishing Switzerland 2016 Dear Sir, tomography, magnetic resonance imaging and endoscopic retrograde cholangiopancreatography. Periportal edema, We have read with interest the paper of Ash et al. [1] along with increased liver volume and mild dilatation of concerning vismodegib-related cholestatic liver injury. We the intrahepatic bile ducts, was noticed (Fig. 1). Minute would like to report our experience with a 71-year-old lithiasic formations were present in the gallbladder, patient who underwent vismodegib therapy for 11 spread choledochus and cystic duct (Fig. 2; Suppl Fig. 1, 2). A cutaneous basal cell carcinoma, of which 4 were recurring single, larger, previously documented, 15 mm lithiasic lesions, and developed intense jaundice by severe element was also evident in the gallbladder. Ash et al. [1] cholestasis and acute liver injury after 3 months of vis- reason on the potential ability of vismodegib to

Journal

Clinical and Experimental MedicineSpringer Journals

Published: Aug 2, 2016

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off